Investment case
argenx SE
ARGX · 4 developments mapped · last assessed 2026-08-27
Market Ontology has mapped 4 macro, policy, and market developments to argenx SE since 2026-08-19. Each one is traced from the driver to the valuation assumption it moves, and the valuation below is run on the same engine the subscription uses.
Valuation
No validated run has been published for ARGX yet, so no modelled value is shown. The ARGX valuation is in the public catch-up queue.
Subscribers do not wait for the weekly cycle: they run ARGX on demand, against live prices and the latest filings, and change any assumption the developments below move.
Filed financials
Current case
- Open question
argenx BV Completes Acquisition of Forte Biosciences, Inc. via Tender Offer
Direct acquisition of a company, impacting financial statements and strategic direction. Integration risks and potential synergies will unfold over time.
· Moves future growth rates, synergy realization, integration costs
What changed, by assumption
- 2026-08-27argenx BV Completes Acquisition of Forte Biosciences, Inc. via Tender Offer
- 2026-08-27argenx Completes Acquisition of Forte Biosciences, Inc.
- 2026-08-19argenx SE satisfies HSR clearance for acquisition of Forte Biosciences, Inc.
- 2026-08-19argenx SE to acquire Forte Biosciences, Inc. for $77.00 per share in cash
Assumption changes
Full ledger →| Date | Assumption | Direction | Why | Conf. |
|---|---|---|---|---|
| 2026-08-06 | Net debt | Bearish | Liability-management transactions often reduce gross debt or push maturities out. | 0.70 |
| 2026-08-06 | Interest expense | Bearish | Tender/exchange extends maturity profile and typically lowers near-term interest expense. | 0.70 |
| 2026-07-27 | Share count | Bullish | Stock component of consideration dilutes existing acquirer holders. | 0.70 |
| 2026-07-27 | Net debt | Bullish | Cash component of consideration is typically debt-funded, raising net debt. | 0.70 |
| 2026-07-27 | Revenue | Bullish | Acquisition adds target revenue to acquirer P&L on close. | 0.70 |
Event impact log
Full ledger →| Date | Mechanism | Direction | Horizon | Impact |
|---|---|---|---|---|
| 2026-08-27 | argenx BV Completes Acquisition of Forte Biosciences, Inc. via Tender Offer | mixed | 3-12m | 0.60 |
| 2026-08-27 | argenx Completes Acquisition of Forte Biosciences, Inc. | mixed | 3-12m | 0.60 |
| 2026-08-19 | argenx SE satisfies HSR clearance for acquisition of Forte Biosciences, Inc. | mixed | 1-5y | 0.60 |
| 2026-08-19 | argenx SE to acquire Forte Biosciences, Inc. for $77.00 per share in cash | mixed | 1-5y | 0.60 |